glp-1 and yeast infections Semaglutide's Impact on Vaginal Health: What You Need to Know Consensus Recommendations on GLP-1 RA

10.1038/ni.2552 Nat

Emanuel, Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity

The same study showed that patients taking higher doses and remaining adherent achieved weight loss comparable to clinical trials

After he had received the combination of all therapies (TPE, UCT-MSC-EXs, Epitalon, and Semax), the patients CNS-VS testing, performed in December 2023 (18 months after baseline testing), showed significant improvement in composite memory, verbal memory, reaction time, and psychomotor speed, going from 2/12 in the average category at baseline to 7/12 in the average category (Table 4)

Avoid them within a 2-hour window of dosing

The WHO guideline specifically recommends GLP-1 therapies for adults with obesity, defined as BMI 30 or higher